You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

The Use of Cabazitaxel in Men with Castrate Resistant Metastatic Prostate Cancer Previously Treated with Docetaxel

ID: CED 23 Oct 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
S. Hotte, A. Haynes, N. Fleshner, A. Loblaw

Patient Population

Adult patients with castrate resistant metastatic prostate cancer who have been previously treated with a docetaxel-containing regimen.

Research Question(s)

Does the use of cabazitaxel, either alone or in combination, for the treatment of patients with castrate resistant metastatic prostate cancer who were previously treated with a docetaxel-containing regimen result in improved outcomes?

Outcomes of interest include overall survival, progression-free survival, time-toprogression, time-to-next treatment, time-to-treatment failure, objective and prostaticspecific antigen (PSA) response rates, pain response rate, palliation, quality of life, and adverse events.

pdf download Summary (PDF) (183.54 KB)
pdf download Full Report (PDF) (384.18 KB)